Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program.